Skip to content
OpenCapital
Get started

NuSkin Enterprises NUS Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

USANA Health Sciences logo
USANA Health SciencesUSNA
$0-100%
Herbalife logo
HerbalifeHLF
——
Ulta Beauty, Inc. logo
Ulta Beauty, Inc.ULTA
——

Other financials

Income statement

See full
Revenue$320.6M-12.0%
Gross profit$214.5M-13.2%
Operating income$4.0M+141%
Net income$1.8M-98.3%
EPS (diluted)$0.04-98.1%

Balance sheet

See full
Cash & equivalents$198.7M-2.5%
Total debt$303.6M-8.2%
Total equity$794.1M+5.3%
Total assets$1.4B-1.1%

Cash flow

See full
Operating cash flow-$3.9M-1,107%
CapEx$13.7M+1.0%
Free cash flow-$17.6M-33.6%

Valuation

See full
Market cap$256.35M-38.2%

Where this comes from

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about NuSkin Enterprises's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NuSkin Enterprises's payments for repurchase of common stock?
NuSkin Enterprises (NUS) reported payments for repurchase of common stock of $5.01M in Q1 2026.
How has NuSkin Enterprises's payments for repurchase of common stock changed year-over-year?
NuSkin Enterprises's payments for repurchase of common stock decreased by 0.0% year-over-year, from $5.01M to $5.01M.
What is the long-term trend for NuSkin Enterprises's payments for repurchase of common stock?
Over 4 years (2021 to 2025), NuSkin Enterprises's payments for repurchase of common stock has grown at a -29.3% compound annual growth rate (CAGR), from $80.42M to $20.04M.